The BRAVE-AA-PEDS study focused on 257 adolescents with severe alopecia areata, investigating the efficacy of baricitinib. The trial demonstrated promising results with 42% achieving significant improvement by week 36, and reassuring safety data.

Tapinarof 1% cream, a once-daily nonsteroidal topical for atopic dermatitis, is being explored for its potential to maintain skin clearance during a “drug holiday.” The ADORING 3 study investigates whether patients with atopic dermatitis can pause tapinarof 1% cream after achieving clear skin while still sustaining therapeutic benefit

Dr Raj Chovatiya presents key late-breaking data from AAD 2025 in atopic dermatitis and psoriasis, focusing on ESK001, icotrokinra, and rocatinlimab. He offers expert insights into the clinical relevance of these findings and explores what they could mean for future treatment approaches in dermatological practice.